You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Incyte on Monday said that the European Commission has approved pemigatinib (Pemazyre) for the treatment of FGFR2 fusion-positive, locally advanced, or metastatic cholangiocarcinoma patients who have progressed after systemic therapy.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?Register for Free.